BioThera Solutions

BioThera Solutions is a Canadian biotechnology company specializing in extracellular vesicle biomanufacturing. It operates a plant-derived extracellular vesicle biomanufacturing platform, with characterization against MISEV2023 standards. The company is based in Ottawa, Canada.

BioThera Solutions was founded to address a critical gap in the extracellular vesicle (EV/exosome) field: the absence of scalable, standardized, and reproducible manufacturing required to bring EV technologies into real-world application. The company operates across three integrated layers: plant-derived EV isolation and MISEV2023-compliant biomanufacturing, rigorous particle characterization, and formulation into finished applications. The same workflow supplies every application built on the platform, and every batch leaves with the Certificate of Analysis behind it.

• 2021.10.15

  Reported2021.10.15

  Bio-Thera and Pharmapark expand their partnership for BAT2206[4]Bio-Thera与Pharmapark扩大BAT2206合作finanznachrichten.de

  Bio-Thera announced licensing and supply agreements with Pharmapark for BAT2206, granting Pharmapark exclusive rights to distribute and market the biosimilar in Russia and other CIS countries.

• Unconfirmed

  Reported2021.08.27

  Bio-Thera and Hikma enter BAT2206 commercialization and license agreement[5]百奥泰与 Hikma 达成 BAT2206 商业化及许可协议finanznachrichten.de

  Bio-Thera Solutions entered into a commercialization and license agreement with Hikma Pharmaceuticals for BAT2206. Hikma received exclusive rights to commercialize the product in the US, while Bio-Thera retained responsibility for development, manufacturing, and supply.

• 2020.08.24

  Reported2020.08.24

  Bio-Thera and BeiGene sign China agreement for BAT1706[6]百奥泰与百济神州签订BAT1706中国授权、分销及供货协议finance.sina.com.cn

  Bio-Thera and BeiGene announced that they had signed an agreement covering the licensing, distribution and supply of Bio-Thera’s investigational biosimilar BAT1706 in China, including Hong Kong, Macao and Taiwan. The agreement was subject to approval at Bio-Thera’s September 2020 shareholders’ meeting.

• 2020.06.16

  Reported2020.06.17

  Bio-Thera announces proposed Hong Kong listing[7]百奥泰公告筹划发行H股并在香港上市finance.sina.com.cn

  Bio-Thera announced that its board had approved a proposal to issue H shares and apply for a main-board listing on the Hong Kong Stock Exchange. The company said it would choose an appropriate time and issuance window within the period authorized by the shareholders’ meeting.

• 2020.06.16

  Reported2020.06.16

  Bio-Thera announces plan for Hong Kong listing[8]百奥泰宣布筹划赴港上市tech.sina.com.cn

  Bio-Thera announced that its board had approved a proposal to issue H shares and apply for a listing on the main board of the Hong Kong Stock Exchange. The company said the timing would be determined later, subject to shareholder authorization, market conditions, and regulatory approvals.

• 2019.11.20

  Reported2019.11.20

  Bio-Thera Therapeutics passed STAR Market IPO review[9]百奥泰科创板IPO通过审核finance.sina.com.cn

  The Shanghai Stock Exchange's STAR Market Listing Committee review results stated that Bio-Thera Therapeutics' STAR Market IPO passed review.

• 2019.11

  Reported2019.11.20

  China approves Bio-Thera’s BAT1406[10]百奥泰BAT1406获中国批准上市finance.sina.com.cn

  China’s National Medical Products Administration approved Bio-Thera’s adalimumab biosimilar BAT1406 for marketing in early November 2019, making it the company’s first approved marketed drug and the first approved domestic biosimilar to Humira.

Read more

1. 1Plant-Derived Extracellular Vesicle Biomanufacturing Platform | BioThera Solutionsbiotherasolutions.com
2. 2About — Plant-Derived EV Biotech Founded in Ottawa | BioThera Solutionsbiotherasolutions.com
3. 3BioThera Solutionswikidata.org
4. 4Bio-Thera与Pharmapark扩大BAT2206合作finanznachrichten.de
5. 5百奥泰与 Hikma 达成 BAT2206 商业化及许可协议finanznachrichten.de
6. 6百奥泰与百济神州签订BAT1706中国授权、分销及供货协议finance.sina.com.cn
7. 7百奥泰公告筹划发行H股并在香港上市finance.sina.com.cn
8. 8百奥泰宣布筹划赴港上市tech.sina.com.cn
9. 9百奥泰科创板IPO通过审核finance.sina.com.cn
10. 10百奥泰BAT1406获中国批准上市finance.sina.com.cn
11. 11百奥泰启动H股上市进程 科创板创新药企欲“A+H”阔步国际化finance.sina.com.cn